background: Laparoscopic electrocautery of the ovaries and ovulation induction with gonadotrophins are both second line treatments for women with clomiphene citrate-resistant polycystic ovary syndrome (PCOS). Long-term follow-up after electrocautery versus ovulation induction with gonadotrophins has demonstrated at least comparable chances for a first live born child with a reduced need for ovulation induction or assisted reproduction treatment and increased chances for a second live born child. In this study, we report on the long-term economic consequences of both treatment modalities. methods: Between February 1998 and October 2001, we performed a multi-centre randomized controlled trial (RCT) comparing a strategy of laparoscopic electrocautery of the ovaries, followed by clomiphene citrate and gonadotrophins when anovulation persisted, and a strategy of ovulation induction with gonadotrophins in women with clomiphene citrate-resistant PCOS. Eight to twelve years after randomization we performed a follow-up study on reproductive outcome in these women and the fertility treatments they had needed including data on direct medical costs of pregnancy and delivery. Clinical data included number of treatment cycles, live births, miscarriages, ectopic pregnancies and multiple pregnancies. We calculated mean costs per woman after randomization until the first live birth. Confidence intervals (CIs) were estimated by bootstrapping.
Introduction
Anovulation related to polycystic ovary syndrome (PCOS) is a frequent cause of female subfertility (Franks, 1995) . Ovulation induction with clomiphene citrate is the first line of treatment (Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). Those 20% of women that do not ovulate on the maximal daily dose of 150 mg are referred to as clomiphene citrate resistant (Imani et al., 1998) . In women with clomiphene citrate-resistant PCOS, laparoscopic electrocautery of the ovaries and ovulation induction with gonadotrophins are effective treatments Farquhar et al., 2007) .
A follow-up study was performed a decade after women had been enrolled in a RCT comparing laparoscopic electrocautery of the ovaries and ovulation induction with gonadotrophins (Nahuis et al., 2011) . Seventy-one of 83 women (86%) who had received electrocautery and 69 of 85 women (81%) who initially had started ovulation induction with recombinant FSH (rFSH) had at least one live born child (Nahuis et al., 2011) . Laparoscopic electrocautery significantly reduced the need for ovulation induction or assisted reproduction treatment (ART). For the first live birth, 44 of 83 women (53%) who had undergone electrocautery needed additional treatment versus 65 of 85 women (76%) who had been treated with rFSH [relative risk (RR): 0.69; 95% confidence interval (CI): 0.55 -0.88].
These clinical data indicate that electrocautery of the ovaries is at least as effective as rFSH for the first child, reduces the need for ovulation induction or ART and is more effective for couples who want to have a second child. Costs do play an important role in deciding which treatment to give to a woman. Data on the economic evaluation of treatment in anovulatory infertility are scarce and only concern shortterm outcome (Farquhar et al., 2004; Van Wely et al., 2004) . We, therefore, assessed the costs of laparoscopic electrocautery of the ovaries compared with a strategy starting with ovulation induction with rFSH in women with clomiphene-resistant PCOS.
Materials and Methods

Study design
We performed a follow-up study of 168 women with clomiphene citrate-resistant PCOS who had been included in a multi-centre RCT, performed between February 1998 and October 2001 in 25 Dutch hospitals. All women included had at least chronic anovulation and polycystic ovaries diagnosed on transvaginal ultrasound and had not ovulated on a maximum of 150 mg clomiphene citrate daily for 5 days. Of the 168 women, 83 women had been allocated to an electrocautery strategy and 85 were allocated to a strategy starting with rFSH. Central computerized allocation had been performed with random blocks, stratified for centre. The ovaries from women allocated to electrocautery were cauterized with a bipolarinsulated needle electrode and each ovary was punctured 5 -10 times, depending on its size .
If women ovulated in six subsequent cycles after electrocautery, no further treatment was given. If anovulation persisted for 8 weeks, treatment was followed by clomiphene citrate. The starting dose was 50 mg/day for 5 days. Treatment was followed by rFSH according to the low-dose step-up regime, if anovulation persisted with clomiphene citrate 150 mg/day for 5 days. The end-point of the original trial was defined as the ongoing pregnancy rate (a viable pregnancy of .12 weeks) within 12 months after randomization. After this period treatment was continued according to a local protocol.
Economic analysis
In January 2009, all 168 women were asked to participate in this follow-up study. Data were obtained by a postal questionnaire and, when the information was not sufficient or consistent, by telephone interviews. The questionnaire had items about child wish, past fertility treatments and reproductive outcome, i.e. live births, miscarriages, ectopic pregnancies, immature deliveries, multiple pregnancies, intrauterine fetal deaths (Nahuis et al., 2011) . A live birth was defined as delivery of a living neonate after 25 weeks of gestation. A miscarriage was defined as a non-viable pregnancy before 12 weeks of gestation. An immature delivery was defined as delivery below a gestational age of 25 weeks. An intrauterine fetal death was defined as the absence of heartbeat at a gestational age .25 weeks.
To obtain details on the total number of treatment cycles and the total treatment dose, we searched the medical files. The informed consent forms of the original trial asked women for their approval to be contacted again in the future for further information on their well-being. This was approved by the METC.
Costs per live birth and total treatment costs for multiple children in the follow-up period of 8 -12 years were calculated. In this analysis, we calculated the mean costs per woman until 6 weeks after delivery for the first live birth. All first live births occurred within a follow-up period of 8 years.
Cost calculations
The economic analysis was performed from a health-care perspective and was based on direct medical costs. To perform this analysis, we collected data on all treatment cycles. We registered type of treatment, number of treatment cycles, medication and total dose used per cycle and number of ultrasound visits. The type of treatment included ovulation induction with clomiphene citrate, rFSH, metformin and additional intrauterine insemination (IUI). Also IVF, ICSI and cryopreservation cycles in both groups were registered.
The cost for the laparoscopic electrocautery was calculated in the original cost-analysis . A standard price was used for each ultrasound visit and this reflected the unit of staff, materials, equipment, housing, depreciation and overheads. The overhead costs are direct medical costs covered by the health-care system.
Costs for stimulation with clomiphene citrate and rFSH were calculated by multiplying the total dose used by the corresponding unit prices based on Dutch wholesale prices (van Loenen, 2009 ). We used assumptions concerning costs from Dutch inventory studies of mean costs for each treatment cycle of IUI, IVF, ICSI and cryopreservation (Bouwmans et al., 2008; Merkus, 2009) (Table I ). The cost for obstetric care for mother and child until 6 weeks after delivery was estimated as E2804 for a singleton pregnancy and delivery and E14 814 for a twin pregnancy and delivery (Lukassen et al., 2004) . We applied all costs to the financial year 2009 using the National price indexes and taking a discount of 5% over a period of 3 years into account.
Statistical analysis
Given the equivalence between the two treatment strategies in terms of a first live birth-the primary outcome measure-our analysis focused on the cost difference between the two strategies within a follow-up time of 8 -12 years. Costs were expressed as means per woman and means per live birth with 95% CI as estimated by bootstrapping. The MannWhitney U test was performed on the mean total cost in the electrocautery group and the rFSH group. Analysis was performed according to intention-to-treat (ITT) principle. The difference was expressed as a mean difference with a bootstrap 95% CI for 10 000 bootstrap samples.
Women were registered as lost to follow-up if the medical files were missing. For women with missing data on the exact dose of rFSH, we assumed that they received the mean dose of the group they had been allocated to. We had no missing data on the exact dose of clomiphene citrate and metformin.
A scenario analysis was performed to evaluate the costs in a scenario without a diagnostic laparoscopy in women who started ovulation induction with rFSH immediately. All analyses were performed with the Statistical Package for the Social Sciences w (SPSS, Inc., Chicago, IL, USA) version 19.0 for Windows and a P-value of 0.05 was used as to indicate statistical significance.
Results
Between February 1998 and October 2001, 168 women had been included in the trial, of whom 83 had been allocated to the electrocautery strategy and 85 to ovulation induction with rFSH. All 25 hospitals participated in this cost-effectiveness analysis. We were able to obtain follow-up data for 159 of the 168 women (95%): 79 of 83 women from the electrocautery group (95%) and 80 of 85 women from the rFSH group (94%).
Baseline characteristics at time of randomization were comparable between the two groups and have been published in the original article. Nahuis et al., 2011) . The mean (SD) baseline FSH level was 6.2 U/l (0.9 U/l) in the electrocautery strategy and 6.3 U/l (0.8 U/l) in the rFSH group.
Details on time to pregnancy and follow-up have been published in the original follow-up study (Nahuis et al., 2011) . The follow-up time was 8-12 years, with a median follow-up time of 134 months in the electrocautery strategy group and 133 months in the rFSH group. For nine women only the 1-year follow-up data were available, which were part of the original randomized trial. Since we performed an ITT analysis we did not exclude these nine women.
First live birth after randomization
After randomization, 71 of 83 women (86%) allocated to electrocautery and 69 of 85 women (81%) allocated to rFSH reached a first live birth (RR: 1.1, 95% CI: 0.92 -1.2). For the first live birth 44 of 83 women (53%) who had undergone electrocautery needed additional treatment versus 65 of 85 women (76%) who had been treated with rFSH (RR: 0.69; 95% CI: 0.55 -0.88). The mean time to a first live birth was 18 months in the electrocautery group and 19 months in the rFSH group.
Average use of resources for the first live birth is presented in Table I . One woman had electrocautery twice. Six women allocated to the rFSH strategy underwent laparoscopic electrocautery in the follow-up.
The mean costs for use of resources are presented in Table II . The mean costs for the operative procedure were E1151 in the electrocautery strategy and E676 in the rFSH strategy. Costs were higher because of a longer operation time and the additional equipment needed for the electrocautery strategy. The mean costs for clomiphene citrate, rFSH and human chorionic gonadotrophin (hCG) plus the additional costs for IUI and IVF and electrocautery were lower Costs after electrocautery in clomiphene resistance for women allocated to the electrocautery strategy (mean difference E2224, 95% CI: E56 -E4393), which is significantly different. Of the 71 women who had a first live birth in the electrocautery group, three delivered a twin (4%). Of the 69 first live births in the rFSH group, 6 (9%) were twin births (RR: 0.49; 95% CI: 0.13 -1.9). The mean (bootstrap 95% CI) total costs for the first live birth, including delivery, as expressed per woman until the first live birth or during the follow-up period after randomization were E9560 (95% CI: E8212-E10 907) for the electrocautery strategy and E11 708 (95% CI E9845-E13 561) for the rFSH strategy, resulting in a difference of E2148 (95% CI: 2E153 to E4450), which is not statistically significant.
When expressed per live birth, the mean costs per first live birth after randomization were E11 176 (95% CI: E9689-E12 549) for the electrocautery group and E14 423 (95% CI: E12 239 -E16 606) for the rFSH group, resulting in significantly lower costs P , 0.05 per first live birth for the electrocautery group (mean difference E3247; 95% CI: E650 -E5814).
All live births after randomization
Of the 140 women that had a first live born child, 90 had a second child, 24 had a third child and 4 had a fourth live born child. Including the second, third and fourth children, the total number of live births during the follow-up period was 134 (52%) in the electrocautery group and 124 (48%) in the rFSH group. Additional treatment was needed in 70 of 134 women (52%) who had undergone electrocautery versus 84 of 124 women (68%) who had been allocated to the rFSH strategy.
Average use of resources for all live births is presented in Table III . The mean costs for the use of resources are presented in Table IV . When all live births were taken into the analysis, the mean treatment cost per woman after 8 to 12 years of follow-up for clomiphene citrate, rFSH and hCG were lower in the electrocautery strategy group than in the rFSH group (cost difference E2188: 95% CI: E1137-E3239). When the costs for IUI and IVF and additional electrocautery were also included, the mean (95% CI) total treatment costs per woman were E8226 (95% CI: E6851-E9601) for the electrocautery strategy versus E10 017 (95% CI: E7749-E12 285) for the rFSH strategy (cost difference: E1791; 95% CI: 2E744 to E4325). Of all live births 241 (93%) were singleton pregnancies and 17 (7%) were multiple pregnancies of which one was a triplet. There were 7 twins out of 134 deliveries (5%) after electrocautery versus 10 twins out of 124 deliveries (8%) in the rFSH strategy (RR: 0.65; 95% CI: 0.25 -1.6). All twin pregnancies occurred in stimulated cycles, of which two such pregnancies occurred after IVF in both study groups. The mean delivery costs were E5820 (95% CI: E4841-E6800) in the electrocautery strategy versus E5628 (95% CI: E4496-E6760) in the rFSH strategy.
The mean total costs, including delivery, per woman in the followup period after randomization were E14 047 (95% CI: E12 318-E15 775) for the electrocautery versus E15 645 (E13 244 -E18 045) for the rFSH strategy (cost difference: E1598; 95% CI: 2E1269 to E4466).
The mean costs per live birth including second, third and fourth children were lower for women allocated to the electrocautery strategy (mean difference E1953; 95% CI: 2E144 to E3762).
Scenario analysis
In this trial, all women underwent a diagnostic laparoscopy. A more realistic scenario would not always require a diagnostic laparoscopy for ovulation induction with rFSH. In case women allocated to rFSH treatment did not undergo a diagnostic laparoscopy, the mean total treatment costs until conception leading to first live birth after randomization in the rFSH treatment arm would be E11 031. The resulting costs difference in favour of the electrocautery strategy would be E1472 per woman (bootstrap 95% CI: -E825 to E3769).
Conclusion
In this long-term economic analysis comparing laparoscopic electrocautery of the ovaries versus ovulation induction with gonadotrophins in clomiphene-resistant women with PCOS, we found that the costs for a first live born baby were just over E2000 lower per women allocated to electrocautery. We also observed that electrocautery significantly eliminated the need for ovulation induction or ART for the first child. If ovulation induction was needed, significantly more clomiphene citrate, but significantly less rFSH was needed. Live birth rates were slightly higher for women allocated to laparoscopic electrocautery of the ovaries.
Our analysis was based on a balanced RCT with a high follow-up rate and ITT analysis. This cost analysis was not performed for a societal perspective, as collecting costs resulting from productivity loss (indirect and time costs) would be vulnerable to recall bias in a retrospective study. As an approximation of the real costs, we extrapolated the cost for the laparoscopic electrocautery, ovulation induction, ART and delivery reported in other trials (Lukassen et al., 2004; van Wely et al., 2004; Merkus, 2009; Bouwmans et al., 2008) and applied all costs for the year 2009. Costs resulting from miscarriage, ectopic pregnancy, immature delivery or intrauterine fetal death were not measured in this analysis, because no solid cost calculations for these pregnancy outcomes are available in the literature. Although not significant, these outcomes were less frequent in women allocated to laparoscopic electrocautery of the ovaries, so this may enlarge the described cost difference (Nahuis et al., 2011) .
We calculated the costs of obstetric care based on prices available in the literature (Lukassen et al., 2004 ). Since we did not observe any differences in the mode of delivery or complication rate between the women allocated to laparoscopic electrocautery or ovulation induction with gonadotrophins, we feel these data are not open to bias. (Nahuis et al., 2011) .
A limitation of the present study is that we do not know the child wish per couple over time.
We want to stress that the groups occurred by randomization at baseline, and thus are completely comparable. External factors could have influenced the effectiveness of both strategies, but the impact of these factors was potentially similar. The larger family size in the electrocautery strategy may be related to the fact that women more often return to normal ovulation after electrocautery, thus allowing women to conceive without further medical assistance.
This economic evaluation represents the costs in The Netherlands. It should be realized that costs of laparoscopic electrocautery and rFSH may differ between countries, and therefore our results cannot unconditionally be generalized to other circumstances.
In our study, all women had a diagnostic laparoscopy to rule out tubal obstruction and adhesions. A scenario analysis without diagnostic laparoscopy preceding rFSH treatment led to a smaller cost difference in favour of electrocautery after randomization. The mean total costs per woman until a live birth after randomization were E9560 for the electrocautery strategy and E11 708 for the diagnostic laparoscopy plus rFSH strategy and E11 031 for rFSH without diagnostic laparoscopy.
Data on the economic evaluation of treatment in anovulatory infertility are scarce and only concern short-term outcome. A RCT comparing the direct and indirect costs of laparoscopic ovarian electrocautery with three cycles of gonadotrophins demonstrated that within 6 months of the initiation of therapy pregnancy outcomes were similar, but the cost of a live birth was one-third lower in the electrocautery strategy, NZ$19 640 versus NZ$29 836, or E11 200 versus E17 000 (Farquhar et al., 2004) . Our own data reveal that the mean total costs per woman until an ongoing pregnancy within 12 months after randomization were slightly lower for women assigned to the electrocautery strategy, E5308 versus E5925. The estimated direct medical cost per term pregnancy including treatment and delivery costs for women allocated to the electrocautery strategy was E11 301, which is 22% lower than in women allocated to rFSH treatment .
We conclude that the mean treatment costs per live birth within 8-12 years after initial treatment are significantly lower per live birth for a strategy that starts with laparoscopic electrocautery compared with a strategy with ovulation induction with rFSH. Together with our previously published results that indicate electrocautery is an effective treatment, these data show that it is prudent to consider electrocautery as a rational treatment option for women with clomiphene-resistant PCOS.
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